GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

DARPA, Alzheimers, PatientAdvocacy, AI and Pharma Corey Hubbafd DARPA, Alzheimers, PatientAdvocacy, AI and Pharma Corey Hubbafd

The Cutting Edge: Innovations in Medical Device Research and Development

The landscape of healthcare is in constant flux, driven by relentless innovation and technological advancement. At the forefront of this evolution lies the field of medical device research and development, a domain dedicated to creating tools and technologies that diagnose, treat, and manage a vast array of medical conditions.

Read More

Early and Accurate Detection of Neurological Diseases: A Pursuit of Breakthrough Solutions

Early and accurate detection of neurological diseases remains one of the most pressing challenges in modern medicine. Neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) often present with subtle symptoms in their initial stages, making early diagnosis difficult and delaying timely interventions. As our global population ages, the prevalence of these debilitating conditions is projected to rise dramatically, further emphasizing the urgent need for reliable diagnostic tools.

Read More

Battling Alzheimer's: A New Hope on the Horizon

Alzheimer's Disease. The very name evokes a sense of dread, a long, slow fading of memory, personality, and ultimately, life itself. It's a condition that not only devastates those who suffer from it but also places an immense emotional and physical burden on their families and caregivers. For years, the scientific and medical communities have been locked in a relentless battle against this formidable foe, striving to understand its origins, slow its progression, and ideally, find a cure.

Read More
Alzheimer's Research, FDA, AI and Pharma Corey Hubbafd Alzheimer's Research, FDA, AI and Pharma Corey Hubbafd

The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game

The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.

Read More

Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science

When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.

"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded

If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.

Read More